
|Articles|August 28, 2014
- Head and Neck Cancers (Issue 1)
- Volume 1
- Issue 1
Results of the SELECT Trial in Thyroid Cancer
Author(s)Martin Schlumberger, MD
Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Advertisement
Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Learn more about targeted agents and radioactive iodine resistance > >
Articles in this issue
about 12 years ago
Unmet Needs in the Treatment of Thyroid Cancerabout 12 years ago
Immunotherapy in Head and Neck Cancersabout 12 years ago
Molecular Markers Emerge in the Diagnosis of Thyroid Cancerabout 12 years ago
Update on Targeted Therapies in Head and Neck Cancersabout 12 years ago
Multidisciplinary Approach to Head and Neck Cancers May Improve OutcomesAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
3
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
4
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
5





































